DSIP
Sleep peptide. DSIP is not FDA approved for any use.
Key facts
- Class
- Sleep peptide
- Also called
- delta sleep-inducing peptide, emideltide
- Vial sizes sold
- 2 mg, 5 mg, 10 mg
- Community-reported sizes
- Half-life
- 4.0 +/- 0.7 min
- intravenous, dog · Neuroendocrinology 1984, PMID 6379493
- FDA status
- Not approved
- Off Category 2, 15 Apr 2026
- PCAC vote
- Not recommended
- Jul 2026, not final
- WADA
- Unclear
- Not named on the 2026 list
DSIP guides
Evidence at a glance
Human and animal counts are PubMed records from our evidence ledger (search counts, not studies we reviewed). The grade is the strongest design among the studies we summarised for that goal: a human randomized trial outweighs any number of animal studies.
| Condition | Human studies | Animal studies | Studies we summarised | Evidence grade |
|---|---|---|---|---|
| Sleep | 76 | 306 | 9 | Human RCT evidence, 4 of 4European journal of anaesthesiology 2009, PMID 19142086 |
Grades follow our evidence scale. Summarised studies come from our evidence file, each quote checked against the abstract or label.
Delta sleep-inducing peptide: 1980s human work, little since
In a six-volunteer double-blind crossover study, a morning intravenous infusion was followed by a 59% rise in median total sleep time over 130 minutes versus placebo.[10]
A larger double-blind insomnia study concluded that short-term DSIP treatment is not likely to be of major therapeutic benefit.[11]
Mixed results, intravenous only
A placebo-controlled study in severe chronic insomnia reported that treatment substantially improved night sleep.[12]
Another controlled trial concluded the sleep improvement was of little clinical significance.[13]
A randomized trial during isoflurane anaesthesia found that DSIP reduced delta rhythm, which the authors describe as paradoxical.[6]
In dogs the half-life was only 4.0 minutes after intravenous dosing; no human half-life was found.[7]
Regulatory path
No FDA-approved DSIP product exists in the Drugs@FDA search, where the substance is searched as DSIP.[4]
FDA removed emideltide (DSIP) from category 2 because the nominations were withdrawn, and set a PCAC consultation for 24 July 2026.[5]
Common questions
Is DSIP FDA approved?
No. DSIP is not FDA approved for any use. The FDA removed it from Category 2 on 15 Apr 2026. Its advisory committee did not recommend it for the 503A compounding list in July 2026.
How much water goes in a 10 mg vial?
That choice only changes the concentration. With 2 mL, the vial is 5 mg/mL. The calculator converts any amount to syringe units. It does the math only and does not suggest a dose.
What is DSIP?
A short peptide called delta sleep-inducing peptide, tested for sleep in small intravenous studies decades ago.[10]
What does DSIP do?
Results conflict: some small trials reported better sleep, but the double-blind insomnia study judged benefit unlikely to be major.[11]
Is there a DSIP nasal spray?
The first human study gave DSIP as slow intravenous infusions; no nasal-spray study was found.[10]
Sources
- 1Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2; 'nominated but withdrawn' table, content current as of 22 Apr 2026)U.S. Food and Drug Administration · 2026fda.govAccessed 2 Oct 2026
- 2Pharmacy Compounding Advisory Committee meeting, 23–24 Jul 2026 (agenda and materials)U.S. Food and Drug Administration · 2026fda.govAccessed 2 Oct 2026
- 3World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 4United States: No FDA-approved product found: Drugs@FDA (openFDA) search for active ingredient "DSIP" returned no matches on 2 Oct 2026.U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
- 5US compounding: DSIP (emideltide) was removed from FDA's 503A category 2 after the nominators withdrew; FDA announced a PCAC consultation on 24 July 2026.U.S. Food and Drug Administration · 2026fda.govAccessed 2 Oct 2026
- 6Delta sleep-inducing peptide alters bispectral index, the electroencephalogram and heart rate variability when used as an adjunct to isoflurane anaesthesia.European journal of anaesthesiology · 2009PMID 19142086Accessed 2 Oct 2026
- 7Development of an enzyme immunoassay for delta sleep-inducing peptide (DSIP) and its use in the determination of the metabolic clearance rate of DSIP administered to dogs.Neuroendocrinology · 1984PMID 6379493Accessed 2 Oct 2026
- 8Advisory committee backs 6 of 7 peptides for the 503A listNCPA · 2026ncpa.org
- 9FDA gives notice that 12 peptides will be removed from Category 2 (nominations withdrawn)FDA · 2026fda.govAccessed 2 Oct 2026
- 10Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior.International journal of clinical pharmacology, therapy, and toxicology · 1981PMID 6895513Accessed 2 Oct 2026
- 11Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study.Neuropsychobiology · 1992PMID 1299794Accessed 2 Oct 2026
- 12Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia.European neurology · 1987PMID 3622582Accessed 2 Oct 2026
- 13Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs.International journal of clinical pharmacology research · 1987PMID 3583493Accessed 2 Oct 2026
Found an error? Report a correction.